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Relaxin family peptide (RXFP) receptors 1 and 2 are unique G-protein coupled receptors
in that they contain an N-terminal low-density lipoprotein type A (LDLa) module which is
necessary for receptor activation.The current hypothesis suggests that upon ligand binding
the LDLa module interacts with the transmembrane (TM) domain of a homodimer partner
receptor to induce the active receptor conformations.We recently demonstrated that three
residues in the N-terminus of the RXFP1 LDLa module are potentially involved in hydropho-
bic interactions with the receptor to drive activation. RXFP2 shares two out of three of the
residues implicated, suggesting that the two LDLa modules could be interchanged without
adversely affecting activity. However, in 2007 it was shown that a chimera consisting of
the RXFP1 receptor with its LDLa swapped for that of RXFP2 did not signal. We noticed
this construct also contained the RXFP2 region linking the LDLa to the leucine-rich repeats.
We therefore constructed chimeric RXFP1 and RXFP2 receptors with their LDLa modules
swapped immediately C-terminally to the final cysteine residue of the module, retaining
the native linker. In addition, we exchanged the TM domains of the chimeras to explore if
matching the LDLa module with theTM domain of its native receptor altered activity. All of
the chimeras were expressed at the surface of HEK293T cells with ligand binding profiles
similar to the wild-type receptors. Importantly, as predicted, ligand binding was able to
induce cAMP-based signaling. Chimeras of RXFP1 with the LDLa of RXFP2 demonstrated
reduced H2 relaxin potency with the pairing of the RXFP2TM with the RXFP2 LDLa neces-
sary for full ligand efficacy. In contrast the ligand-mediated potencies and efficacies on the
RXFP2 chimeras were similar suggesting the RXFP1 LDLa module has similar efficacy on
the RXFP2 TM domain. Our studies demonstrate the LDLa modules of RXFP1 and RXFP2
modulate receptor activation via a similar mechanism.
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INTRODUCTION
Relaxin family peptide receptor (RXFP) 1 and RXFP2 are class A
G-protein coupled receptors (GPCR). They are therefore mem-
bers of the largest gene family in humans (1), and GPCRs are
currently the target of more directed drugs than any other gene
family (2). While RXFP1 and RXFP2 both possess the representa-
tive 7 transmembrane (TM) spanning α-helices, they also contain
a large extracellular domain, consisting of 10 leucine-rich repeats
(LRR) tethered to a single low-density lipoprotein type A (LDLa)
module (3) by an uncharacterized linker. The LRRs are the pri-
mary binding site for the cognate ligands, relaxin (RXFP1) and
insulin-like peptide 3 (INSL3) (RXFP2), while the LDLa module
is essential for signaling (4). As the receptors have been shown
to form constitutive homodimers (5, 6) it is hypothesized that
the LDLa module acts as a secondary ligand, possibly interacting
with the extracellular loops of the TM region of a homodimer
partner receptor to induce the conformational change necessary
for signaling (7). RXFP1 and RXFP2 are the only known mam-
malian GPCRs to contain an LDLa module and thus the potential
role of this module in signal activation is unique. The module
itself requires the formation of three disulfide bonds between
six conserved cysteine residues, as well as the presence of a sin-
gle bound calcium ion to maintain its active, globular structure
(8). Replacing the native LDLa module of RXFP1 with the struc-
turally similar but functionally distinct LB2 module from the
low-density lipoprotein receptor (LDLR) gives rise to a chimera
that can bind ligand like the wild-type (WT), but cannot signal
(8, 9). The RXFP1-LB2 chimera was used to identify key residues
needed for signaling in a gain-of function study complemented
with equivalent loss-of-function mutations and a detailed struc-
tural analysis (9). In this way a prospective binding surface was
identified involving Leu7, Tyr9, and Lys17, which are proposed
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to contribute to the activation of RXFP1 using hydrophobic
contacts.
A similar mechanism of action of the LDLa module by the
two receptors is implied by the degree of sequence similarity
they share. The LDLa modules of RXFP1 and RXFP2 share 60%
sequence similarity (Figure 1), each possessing features common
to other LDLa modules characterized from the LDLR includ-
ing the six cysteines that form disulfide bonds, and the motif
AspxxxAspxxAspxxAspGlu (where x is any residue) that binds a
calcium ion. Many LDLa modules characterized from the LDLR
utilize this motif to not only ligate the calcium ion but contribute
to protein–protein interactions (10), while residues important to
RXFP1 function have been mapped to the N-terminal region of
the LDLa (9). Two residues key to the function of RXFP1, Tyr9,
and Lys17, are conserved in the RXFP2 LDLa module and it is
reasonable to assume they function in a similar manner to induce
signal activation. Importantly, it has been shown that chimeras,
named RXFP1/2 and RXFP2/1, in which the entire ectodomain of
the receptors are swapped are still able to signal, albeit with low-
ered activity compared to WT (11). This implies that the LDLa
module of RXFP2 can compensate for the module of RXFP1 and
vice versa. It would seem reasonable to assume then that simply
swapping the LDLa modules between RXFP1 and RXFP2 would
also yield chimeras capable of signaling. However, in a study by
Kern and colleagues in 2007 where they replaced the RXFP1 LDLa
module with that of RXFP2, they reported that the chimera did
not signal, concluding that the cAMP signaling function of RXFP1
was only possible with its native LDLa module (12).
The present study aims to further investigate this seeming con-
tradiction, and establish why an ectodomain-swapped chimera
of RXFP1 with RXFP2 can signal, while an equivalent LDLa-
swapped chimera cannot. Upon scrutiny of the constructs made
by Kern et al., it would appear that the point chosen to swap
the LDLa modules was 27 residues C-terminally to the final cys-
teine (Cys40) necessary for LDLa structural integrity for RXFP1.
Importantly, the equivalent region of RXFP2 which was replaced
            1   5    10   15   20   25   30   35   40
RXFP1   QDVKCSLGYFPCGNITKCLPQLLHCNGVDDCGNQADEDNC
RXFP2  MITPSCQKGYFPCGNLTKCLPRAFHCDGKDDCGNGADEENC
           1   5    10   15   20   25   30   35   40
           
LDLa module 
  41  45   50   55   60   65   70 
RXFP1 GDNNGWSLQFDKYFASYYKMTSQYPFEAETPE
RXFP2 GDTSGWATIFG-------TVHGNANSVALTQE
42 45   50          55   60   65
LDLa/LRR linker 
FIGURE 1 | Alignment of the RXFP1 and RXFP2 LDLa module and
linker sequences. Identical residues are boxed in black and similar residues
are boxed in gray while the conserved cysteine residues are boxed in red.
The residues recently identified as being involved in RXFP1 ligand-mediated
activation (9) are highlighted in blue in both RXFP1 and where they are
conserved in RXFP2. A blue arrow shows where our swapped modules are
cleaved. Red arrows show the point of cleavage for the swapped modules
in the chimera made by Kern et al. (12).
in the chimera is seven amino acids shorter (Figure 1), meaning
that the resulting chimera had a shorter stretch of amino acids
linking the LDLa module to the LRRs than WT RXFP1. We there-
fore designed chimeric constructs of both RXFP1 and RXFP2 that
had their LDLa modules swapped immediately C-terminally to
the aforementioned cysteine similar to our RXFP1-LB2 chimera
(8), meaning that only the LDLa module itself was swapped, and
none of the adjoining linker residues. We call these constructs
RXFP211 and RXFP122 (Figure 2) based on the nomenclature
utilized previously for ectodomain-swapped RXFP1 and RXFP2
receptors (11). As further investigation into the possibility of a
receptor-specific interaction between the LDLa module and the
TM domain, we also matched the LDLa module with the comple-
mentary TM domain, to establish if an improvement in signaling
activity would be observed. These constructs are named RXFP212
and RXFP121 (Figure 2). The resulting chimeras were tested for
surface expression, binding of ligand, and cAMP-based signaling.
MATERIALS AND METHODS
HORMONES AND CELL LINES
Recombinant human gene-2 relaxin (H2 relaxin) peptide was
kindly provided by Corthera and human INSL3 was chemically
synthesized as previously described (13). Human embryonic kid-
ney (HEK) 293T cells (ATCC #CRL-1573; American Type Tissue
Culture Collection) used to express receptors were maintained in
Dulbeccos’ modified eagle medium (DMEM) supplemented with
10% fetal bovine serum (FBS), 1% l-glutamine and 1% peni-
cillin/streptomycin (referred to as complete DMEM) in incubators
(Thermo scientific) maintained at 37°C, with 5% CO2 and 85%
humidity.
RECEPTOR CONSTRUCTS
RXFP1, RXFP2, and chimeric constructs were cloned into a
pcDNA3.1™/Zeo+ AmpR mammalian expression vector (Invit-
rogen, Carlsbad, CA, USA) which contained an N-terminal FLAG
tag and a bovine prolactin signal sequence (3) and has been shown
not to interfere with receptor activity (14). The chimeric receptor
constructs were made using overlap PCR. The LDLa modules were
first generated using the relevant LDLa module as template and
PCR primers that would anneal to the two ends of the LDLa mod-
ule (Table 1). The amplification PCR mixture contained 100 ng
of DNA template, 10µl of 10× PCR buffer, 1µl of each primer,
0.5µl of dNTP mix, 2µl of MgCl2, 0.5µl of Taq (Bioline Veloc-
ity) and distilled, de-ionized water to make up to a total of 50µl.
PCR conditions were 2 min at 98°C, then 30 cycles of 98°C (30 s),
58°C (30 s), 72°C (15 s) followed by a 7 min extension at 72°C.
The LRR/TM regions of each construct were similarly amplified
(Table 1) and the two sections of DNA were annealed together
in a PCR reaction consisting of 200 ng of LDLa DNA, 50 ng of
LRR/TM DNA, 10µl of 5× PCR buffer, 1µl of dNTP mix, 0.25µl
of Taq polymerase (Bioline Velocity), and made up to 50µl with
distilled, de-ionized water. The conditions used were 98°C (2 min)
then 10 cycles of 98°C (30 s), 50°C (25 min), 72°C (5 min). The
final annealed product was then amplified using the same proto-
col as in the other amplification steps, except that the 72°C step
was carried out for 30 s instead of 15 s. Primers used were the for-
ward (sense) primer used to amplify the LDLa sequence and the
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FIGURE 2 | Schematic representation of the RXFP1 and RXFP2 receptors compared to the RXFP211, RXFP122, RXFP212, and RXFP121 chimeric
receptors. The domains of receptors are labeled on the RXFP1 receptor. RXFP1 domains are in blue while RXFP2 domains are in red.
Table 1 | Primers used in overlap cloning.
Construct component Template DNA Primer (5′–3′ DNA sequence)
RXFP2 LDLa RXFP2 LDLa module Sense: CATCATGGATCCGCCACCATGGACAGCAAAG
Antisense: CAGAGACCATCCATTGTTGTCTCCACAGTTCTCTTCGTCCGCCCC
RXFP1 LDLa RXFP1 LDLa module Sense: CATCATGGATCCGCCACCATGGACAGCAAAG
Antisense: CGCCCATCCACTAGTGTCACCACAGTTGTCCTCATCGGCCTG
RXFP211 LRR and TM RXFP1 Sense: GGGGCGGACGAAGAGAACTGTGGAGACAACAATGGATGGTCTCTG
Antisense: GAGAGCTCGAGTCATGAATAGGAATTGAGTCTCGTTG
RXFP212 LRR and TM RXFP1/2 Sense: GGGGCGGACGAAGAGAACTGTGGAGACAACAATGGATGGTCTCTG
Antisense: CATCATCATCTCGAGCTAGGAAACTGGTTTCATTATACTGTC
RXFP122 LRR and TM RXFP2 Sense: CAGGCCGATGAGGACAACTGTGGTGACACTAGTGGATGGGCG
Antisense: CATCATCATCTCGAGCTAGGAAACTGGTTTCATTATACTGTC
RXFP121 LRR and TM RXFP2/1 Sense: CAGGCCGATGAGGACAACTGTGGTGACACTAGTGGATGGGCG
Antisense: GAGAGCTCGAGTCATGAATAGGAATTGAGTCTCGTTG
reverse (antisense) primer used to amplify the LRR/TM sequence
for each construct (Table 1). The DNA was then digested with
BamHI and XhoI to create sticky ends that would correspond
to sites in fresh, verified, and digested pcDNA3.1 Zeo+ vector.
Ligation was carried out using T4 DNA ligase (Promega) at 4°C
overnight or at room temperature for 3 h. The vectors were then
transformed into DH5α E. coli cells using the heat shock method
and resultant colonies were picked and grown before isolating the
plasmid DNA using a PureLink® Quick Plasmid Miniprep Kit.
The entire insert of successful clones were sequenced to ensure the
desired end product was correct, with no unintentional mutations
incorporated.
RECEPTOR EXPRESSION ON HEK 293T CELLS
Transient transfections were performed using lipofectAMINE™
2000 (Invitrogen) according to the manufacturer’s instructions.
For competition binding assays chimeric receptors were selected
for semi-stable expression and compared with cells stably express-
ing RXFP1 or RXFP2 (9). Semi-stable expression was achieved by
selection of cells with Zeocin after transient transfection followed
by fluorescence activated cell sorting (FACS) using a fluorescently
tagged FLAG antibody 1 week later. For FACS analysis, cells were
seeded in 10 cm dishes at 3× 106 cells, and grown overnight. The
following day the cells were washed and resuspended in 1% FBS
in phosphate buffered saline (PBS) (Gibco) (FBS/PBS) medium.
Alexa 647 labeled anti-FLAG antibody (Invitrogen) was added at
a 1:1000 dilution in FBS/PBS and cells were incubated on ice
for 30 min, then passed through a filter and sorted using FACS
(Becton Dickinson FACS Aria III). Only the top 10% of cells
with fluorescence levels significantly higher than the background
fluorescence in non-transfected HEK293T control cells were col-
lected. The sorted cells were grown in complete DMEM in the
presence of 200µg/ml Zeocin until confluent. HEK293T cells sta-
bly expressing WT RXFP1 were used as a positive control in the
FACS sort.
CELL SURFACE EXPRESSION ASSAYS
The presence of the chimeric receptors at the surface of cells was
assessed in triplicate, exploiting the FLAG epitope on their N-
termini using the method described previously (15). Briefly, cells
were transfected with receptor of interest for 24 h. Next, cells were
fixed with 3.7% formaldehyde solution (Sigma-Aldrich), blocked
with bovine serum albumin (BSA) and incubated with an anti-
FLAG mouse monoclonal primary antibody (Sigma-Aldrich).
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Goat anti-mouse Alexa Fluor 488 was used as secondary anti-
body (Invitrogen). Finally, cells were lysed and transferred into
black-walled 96-well plates for measurement using a BMG plate
reader (Omega) at 495 nm excitation and 519 nm emission wave-
lengths. Data were analyzed using GraphPad PRISM (Graphpad
Software, Inc.) and presented as mean percentage of WT RXFP1
or RXFP2 expression± SEM of at least three independent exper-
iments. Significance of receptor expression above background
and compared to WT was assessed using one-way ANOVA and
uncorrected Fisher’s LSD multiple comparison test.
LIGAND BINDING ASSAYS
Competition binding assays were performed on whole cells as
described previously, using Europium labeled INSL3 (Eu-INSL3)
(16) and Europium labeled H2 relaxin (Eu-H2 relaxin) (17).
Increasing concentrations of unlabeled ligand were used in con-
junction with labeled equivalents, and non-specific binding was
established using 1µM unlabeled ligand. Readings were taken
in triplicate and read on a BMG plate reader (Omega) in clear-
bottomed, opaque-walled 96-well plates (PerkinElmer). Data were
analyzed using GraphPad PRISM and presented as mean per-
centage specific binding± SEM of at least three independent
experiments. A non-linear regression one-site binding curve was
then fitted and resulting pIC50 values were subjected to one-way
ANOVA and uncorrected Fisher’s LSD comparison test.
cAMP ACTIVITY ASSAYS
Cells were assayed for cAMP signaling by co-transfection of recep-
tors with a pCRE β-galactosidase (β-gal) reporter construct as
previously described (18). Cells were stimulated for 6 h at 37°C
with H2 relaxin or INSL3 at dilutions varying from 1µM to
0.001 nM. Pooled data from at least three separate experiments,
each performed in triplicate were presented as percentages of
the maximum response induced by 5µM Forskolin± SEM. A
non-linear regression sigmoidal dose-response curve was then fit-
ted using GraphPad PRISM and resulting pEC50 and maximum
response (Emax) values were subjected to one-way ANOVA and
uncorrected Fisher’s LSD comparison test.
RESULTS
CHARACTERIZATION OF RXFP211 AND RXFP212
Cell surface expression assays on the chimeric constructs showed
that all receptors were expressed at the cell membrane, since their
fluorescence profiles were consistently equal to or greater than
that displayed by the WT receptors (Figure 3). Both RXFP211
and RXFP212 were expressed more highly than WT RXFP1,
which is consistent with findings by Kern et al. for their LDLa-
swapped chimera (12). However, only RXFP211 showed signifi-
cantly (p< 0.01) higher expression than RXFP1 (141.2± 11.3%
of RXFP1 expression) (Figure 3; Table 2).
The construct RXFP211 is made up of the LDLa module from
RXFP2 and the LRRs and TM domain of RXFP1. RXFP212 con-
tains the same domains except that the TM domain is from RXFP2
(Figure 2). As high affinity ligand binding is driven by the LRRs,
binding was assessed in comparison to RXFP1 using a competition
binding assay with Eu-H2 relaxin. As expected binding was unal-
tered in comparison to WT as the LRR sequence was equivalent to
the native receptor in each of the constructs (Figure 4A).
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FIGURE 3 | Cell surface expression of chimeric receptors compared to
the RXFP1 and RXFP2 wild-type (WT) receptors. Data are expressed as
mean±SEM of triplicate determinations from at least three independent
experiments. **p<0.01 compared to RXFP1.
The two LDLa-swapped receptors were tested for cAMP pro-
duction using a reporter gene assay. As the RXFP211 chimera had
significantly different cell surface expression to RXFP1 the results
have been normalized to cell surface expression for this construct
only. While both chimeras were able to induce cAMP activity in
response to H2 relaxin, the potency was reduced, with the pEC50 of
H2 relaxin on RXFP211 being 10.28± 0.15, and that of H2 relaxin
on RXFP212 9.19± 0.03, the latter of which is significantly differ-
ent (p< 0.01) from WT RXFP1 (pEC50 10.89± 0.03) (Figure 4B;
Table 2). Importantly the efficacy of H2 relaxin-induced cAMP
responses at RXFP211 was significantly reduced compared to
RXFP1 with a maximum Forskolin response of 64.02± 3.4%
compared with 102.4± 3.3% (p< 0.05). The replacement of the
RXFP1 TM domain with that of RXFP2 in RXFP212 restored the
H2 relaxin stimulated efficacy to 99.9± 5.3% Forskolin response
(Figure 4B; Table 2).
CHARACTERIZATION OF RXFP122 AND RXFP121
RXFP122 has the TM and LRR domains from RXFP2 and the
LDLa module from RXFP1. RXFP121 has the LDLa module and
the TM region from RXFP1 and the LRRs from RXFP2 (Figure 2).
Cell surface expression for these two constructs was not signifi-
cantly different from WT RXFP2 levels (Figure 3; Table 2). Binding
assays also showed similar patterns of binding to RXFP2, although
pIC50 values for INSL3 binding were found to be significantly
different from RXFP2 (p< 0.05 for RXFP121 and p< 0.01 for
RXFP122) (Figure 5A; Table 2). Given that the constructs had the
LRR region from RXFP2, we tested them for signaling with both
INSL3 and H2 relaxin, as these ligands are both known to activate
RXFP2 (3). While the pEC50 values were not significantly different
from RXFP2 on INSL3 stimulation, they were reduced from the
9.13± 0.06 seen in RXFP2 in response to H2 relaxin to 7.95± 0.10
for RXFP122 (p< 0.01) and 8.22± 0.17 for RXFP121 (p< 0.05)
(Figures 5B,C; Table 2). Importantly, ligand-mediated maximum
responses (Emax) did not differ significantly from RXFP2.
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Table 2 | Pooled binding affinity (pIC50), cell surface expression and cAMP activity (pEC50 and Emax) data for chimeric receptors in comparison
to RXFP1 and RXFP2.
Receptor Cell surface
expression
Eu-H2 relaxin
competition
binding (pIC50)
Eu-INSL3
competition
binding (pIC50)
INSL3 stimulation H2 relaxin stimulation
pEC50 Emax (%Forskolin) pEC50 Emax (%Forskolin)
% RXFP1
RXFP1 100±3.23 (8) 8.77±0.10 (7) ND ND ND 10.89±0.07 (4) 102.4±3.3 (3)
RXFP211 141.2±11.3 (7)** 8.64±0.15 (8) ND ND ND 10.28±0.15 (3) 64.5±3.4 (3)*
RXFP212 109.7±14.7 (5) 8.43±0.17 (4) ND ND ND 9.19±0.03 (3)** 99.9±5.3 (3)
% RXFP2
RXFP2 100±3.5 (4) ND 8.79±0.06 (6) 10.26±0.42 (3) 115.1±9.2 (3) 9.13±0.06 (3) 102.6±16.5 (3)
RXFP122 94.5±10.7 (4) ND 8.35±0.08 (6)## 9.67±0.20 (5) 93.9±3.6 (5) 7.95±0.10 (6)## 109.8±5.0 (6)
RXFP121 91.0±9.8 (5) ND 8.43±0.17 (3)# 10.40±0.34 (5) 93.7±14.6 (5) 8.22±0.17 (4)# 101.4±8.8 (4)
*p < 0.05; **p < 0.01 vs. RXFP1; #p < 0.05; ##p < 0.01 vs. RXFP2; ND – not determined.
FIGURE 4 | Activity of RXFP1 chimeric receptors compared to RXFP1.
(A) Competition binding using Eu-labeled H2 relaxin. (B) H2 relaxin-induced
cAMP responses. cAMP activity is expressed as the percentage of the
5µM Forskolin-stimulated response for each receptor. Note the data for the
RXFP211 receptor has been normalized for cell surface expression (see text
for details). Data are expressed as mean±SEM of triplicate determinations
from at least three independent experiments.
DISCUSSION
The activation mechanisms of RXFP1 and RXFP2 represent a
unique paradigm in GPCR functioning, since these are the only
two mammalian GPCRs that possess an LDLa module. When
found in the LDLR and related receptors, these modules are
typically involved in protein–protein interactions, and are thus
involved in a variety of interactions both with peptides and other
molecules (19). The evidence suggests that the LDLa modules
on the RXFP receptors are also involved in protein interaction,
although rather than being involved in ligand binding, we have
hypothesized that the LDLa module binds with another domain
on the receptor, and that this interaction is necessary to induce the
conformational changes needed for signaling to occur (7). Never-
theless, while in most LDLR family receptors the binding surface
of the LDLa modules seems to involve C-terminal residues, which
are also involved in Ca2+ binding (10, 20), the RXFP1 LDLa mod-
ule appears to have a binding surface that involves residues in
the N-terminal region, and the hydrophobic regions of the side-
chains of Leu7, Tyr9, and Lys17 have been implicated in mutational
investigations on RXFP1 (9). Both Tyr9 and Lys17 are conserved
between RXFP1 and RXFP2 (Figure 1), and although they may
interact differently in each case, their presence implies a similar
mechanism of activation in the two receptors, also suggesting the
LDLa modules of each receptor could be swapped with limited
effect on receptor activation. It was therefore surprising that it
was reported that when the LDLa module of RXFP2 was swapped
into RXFP1 that the chimeric receptor was inactive (12). However
upon investigation of the chimeric receptor design we noted that
the authors had designed the chimeric construct with additional
amino acid residues from the RXFP2 linker region C-terminal of
the LDLa module. Importantly this region of RXFP2 is shorter
than that in RXFP1 and therefore when the chimera was produced
the linker between the LRRs and the LDLa of the chimeric RXFP1
receptor was seven amino acids shorter. In this study we there-
fore first designed a chimeric RXFP1/RXFP2 receptor construct
whereby the RXFP2 LDLa module was swapped at the C-terminal
cysteine residue of the module. By reducing the swapped domain
to its functional minimum length and size, we were able to pro-
duce a functional RXFP211 receptor as hypothesized, although the
efficacy of signaling was reduced compared to the native receptor.
Hence it is likely that the inactivity of the Kern chimeric RXFP1
construct was due to the shortening of the linker region between
the LRRs and LDLa rather than the swapping of the LDLa modules.
While Kern et al. only made the RXFP1 chimera with the LDLa
module of RXFP2 attached,we sought to characterize both this and
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FIGURE 5 | Activity of RXFP2 chimeric receptors compared to RXFP2.
(A) Competition binding using Eu-labeled INSL3. (B) INSL3-induced cAMP
responses. (C) H2 relaxin-induced cAMP responses. cAMP activity is
expressed as the percentage of the 5µM Forskolin-stimulated response for
each receptor. Data are expressed as mean±SEM of triplicate
determinations from at least three independent experiments.
the equivalent RXFP2 construct with the LDLa from RXFP1. We
hypothesized that such chimeras would be informative in relation
to common and distinct mechanisms of activation by the LDLa
module. Additionally, we explored the concept that the LDLa is
exerting its effect by interacting with the TM domain of the recep-
tor in a specific manner by creating LDLa chimeras with matched
TM domains in RXFP121 and RXFP212. The chimeric receptors
were all expressed at the cell surface indicating they were folded
correctly and able to be trafficked to the cell surface. The RXFP211
chimera had significantly higher cell surface expression as pre-
viously demonstrated for the chimera produced by Kern et al.
(12). Binding affinities of both RXFP1 and RXFP2 chimeras were
slightly lower than the WT receptors with only the RXFP2 chimeras
being statistically different. These differences are likely due to the
lower expression levels of the receptors in the cells used for lig-
and binding. The sensitivity of the binding assays requires stable
or semi-stable cell lines and the expression levels of the RXFP1
and RXFP2 stables were considerably higher as they were high
expressing monoclonal stable lines (data not shown). These lower
expression levels would influence the pIC50 values and unfortu-
nately there was not sufficient Eu-labeled ligand to perform satu-
ration binding to obtain K d values. However, we have previously
demonstrated that RXFP1 and RXFP2 receptors lacking the LDLa
module bind ligand normally (4). Hence the slight reductions in
pIC50 values are unlikely to be related to the LDLa module swaps.
As anticipated the chimeric receptors did show differences in
ligand-mediated cAMP activity compared to the WT receptors.
This was most obvious for the RXFP1 chimeras where H2 relaxin
demonstrated both decreased potency as well as decreased % max-
imum Forskolin activity on RXFP211. The shift in pEC50 was sim-
ilar to what we have previously demonstrated when the key RXFP1
LDLa residue Leu7 is mutated to Lysine as it is in the RXFP2 LDLa
module (9). The decreasedEmax values may reflect the mismatch of
the LDLa with the TM domain resulting in the RXFP2 LDLa mod-
ule acting like a partial agonist on the RXFP1 receptor. Notably, we
have seen similar decreases in Emax with multiple mutations of the
RXFP1 LDLa module (8, 9). Furthermore, H2 relaxin activation
of RXFP1-LB2 gain-of-function receptors also resulted in lower
Emax values compared to RXFP1 (9). Interestingly the replace-
ment of the TM domains with that from RXFP2 in the chimera
RXFP212 resulted in full H2 relaxin stimulated efficacy but cou-
pled with lower potency. Hence the RXFP2 LDLa module is now
acting more like a full agonist as potentially the matching of the
LDLa module and the TM domain allows for optimal interactions
to increase the probability of the receptor becoming fully activated.
The decreased ligand potency on RXFP212 may be due to subtle
differences in the LRRs that confer decreased coupling efficiency
between ligand binding and LDLa mediated activation. Similarly,
because RXFP1 and 2 are multi-domain receptors, it is these subtle
mismatches (in LRRs and TM domains) that lead to the changes
in ligand potency seen in all the chimeric receptors. Our previ-
ous studies with RXFP2 LRR chimeric receptors have highlighted
that changes in the ectodomain structure have profound effects on
ligand-mediated activation (21). Furthermore, as indicated above
in the gain-of-function analysis using the RXFP1-LB2 construct,
full restoration of signaling was not obtained, despite inclusion of
sequence that corresponded to the three-dimensional structure of
the interactive surface of the RXFP1 LDLa module (9). In contrast
the RXFP2 chimeric receptors had more modest effects on recep-
tor activity with only a slight decrease in the potency of H2 relaxin
at both chimeras which may reflect the different mechanism by
which H2 relaxin binds and activates RXFP2 (21, 22). The similar
activity of the two chimeras is in contrast to the RXFP1 chimeras
and may reflect the fact that H2 relaxin is a ligand of both receptors
and the RXFP2–INSL3 interaction evolved more recently (23, 24).
Hence the RXFP1 LDLa module may have equal efficacy on the
RXFP2 TM domains. This hypothesis is supported by the similar
efficacy of ligands on the previously reported RXFP1/2 chimera
(11) which matches an RXFP1 LDLa with the RXFP2 TM domain
in addition to the reduced ligand efficacy on the RXFP2/1 chimera
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in this same study (11) again highlighting a partial agonist effect
of the RXFP2 LDLa on the RXFP1 TM domain.
It should also be pointed out that it is highly unlikely that
changes in potency or efficacy in the receptor chimeras is related
to decreased efficiency of homodimerization of the receptors. Our
previous studies on dimerization of RXFP1 (6) and RXFP2 (5)
have demonstrated that homodimerization is primarily driven by
TM interactions with some potential stabilizing influence of the
ectodomains. As the TM and LRR regions would be matched in
homodimers of the chimeric receptors and there was no evidence
of profound changes in cell surface expression or efficacy changes
on our chimeras or with RXFP1/2 and RXFP2/1 previously (11),
it is therefore likely that the chimeric receptors are constitutive
homodimers like the WT receptors.
Taken together, this study has shown that the LDLa modules of
RXFP1 and RXFP2, which are unique among GPCRs, behave in
a comparable fashion to one another, and that their mechanism
of action must therefore be closely related. Additionally it is clear
that the length of the linker region between the LRRs and the LDLa
module is important for RXFP1 function. This information can
be used to further elucidate a model of activation, as we gradu-
ally clarify the myriad of different elements that come into play
upon binding and activation of these complex receptors. Given
that relaxin has been implicated in various pathologies including
cancer (25) and that it is has recently successfully completed a
phase 3 clinical trial for the treatment of chronic heart failure (26)
any knowledge of the activation of its cognate receptor and family
members leads us closer to the development of small molecule
analogs and antagonists that may be therapeutically relevant.
ACKNOWLEDGMENTS
The authors thank Sharon Layfield and Tania Ferraro for technical
assistance and Corthera for provision of recombinant H2 relaxin.
This research was supported by National Health and Medical
Research Council of Australia project grants 628427 and 1043750
(Ross A. D. Bathgate and Paul R. Gooley) and by the Victorian
Government Operational Infrastructure Support Program. Ross
A. D. Bathgate and John D. Wade are recipients of NHMRC (Aus-
tralia) Research Fellowships, Daniel J. Scott is a recipient of an
NHMRC CJ Martin Fellowship, Roy C. K. Kong is the recipient
of a University of Melbourne International Research Scholarship
and University of Melbourne International Fee Remission Schol-
arship and Emma J. Petrie is the recipient of a Melbourne Research
Fellowship (Career Interruptions).
REFERENCES
1. Stevens RC, CherezovV, KatritchV,Abagyan R, Kuhn P, Rosen H, et al. The GPCR
Network: a large-scale collaboration to determine human GPCR structure and
function. Nat Rev Drug Discov (2013) 12:25–34. doi:10.1038/nrd3859
2. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there?
Nat Rev Drug Discov (2006) 5:993–6. doi:10.1038/nrd2199
3. Hsu SY, Nakabayashi K, Nishi S, Kumagai J, Kudo M, Sherwood OD, et al. Acti-
vation of orphan receptors by the hormone relaxin. Science (2002) 295:671–4.
doi:10.1126/science.1065654
4. Scott DJ, Layfield S, Yan Y, Sudo S, Hsueh AJ, Tregear GW, et al. Characterization
of novel splice variants of LGR7 and LGR8 reveals that receptor signaling is
mediated by their unique low density lipoprotein class A modules. J Biol Chem
(2006) 281:34942–54. doi:10.1074/jbc.M602728200
5. Svendsen AM, Zalesko A, Kønig J, Vrecl M, Heding A, Kristensen JB, et
al. Negative cooperativity in H2 relaxin binding to a dimeric relaxin family
peptide receptor 1. Mol Cell Endocrinol (2008) 296:10–7. doi:10.1016/j.mce.
2008.07.014
6. Svendsen AM, Vrecl M, Knudsen L, Heding A, Wade JD, Bathgate RAD, et al.
Dimerization and negative cooperativity in the relaxin family peptide receptors.
Ann N Y Acad Sci (2009) 1160:54–9. doi:10.1111/j.1749-6632.2009.03835.x
7. Bathgate RAD, Halls ML, Van Der Westhuizen ET, Callander GE, Kocan M,
Summers RJ. Relaxin family peptides and their receptors. Physiol Rev (2013)
93:405–80. doi:10.1152/physrev.00001.2012
8. Hopkins EJ, Layfield S, Ferraro T, Bathgate RA, Gooley PR. The NMR solu-
tion structure of the relaxin (RXFP1) receptor lipoprotein receptor class A
module and identification of key residues in the N-terminal region of the
module that mediate receptor activation. J Biol Chem (2007) 282:4172–84.
doi:10.1074/jbc.M609526200
9. Kong RC, Petrie EJ, Mohanty B, Ling J, Lee JC, Gooley PR, et al. The relaxin
receptor (RXFP1) utilises hydrophobic moieties on a signalling surface of its N-
terminal low density lipoprotein class A module to mediate receptor activation.
J Biol Chem (2013) 288:28138–51. doi:10.1074/jbc.M113.499640
10. Fisher C, Beglova N, Blacklow SC. Structure of an LDLR-RAP complex reveals
a general mode for ligand recognition by lipoprotein receptors. Mol Cell (2006)
22:277–83. doi:10.1016/j.molcel.2006.02.021
11. Halls ML, Bond CP, Sudo S, Kumagai J, Ferraro T, Layfield S, et al. Multiple
binding sites revealed by interaction of relaxin family peptides with native and
chimeric relaxin family peptide receptors 1 and 2 (LGR7 and LGR8). J Pharmacol
Exp Ther (2005) 313:677–87. doi:10.1124/jpet.104.080655
12. Kern A, Agoulnik AI, Bryant-Greenwood GD. The low-density lipoprotein class
A module of the relaxin receptor (leucine-rich repeat containing G-protein
coupled receptor 7): its role in signaling and trafficking to the cell membrane.
Endocrinology (2007) 148:1181–94. doi:10.1210/en.2006-1086
13. Rosengren KJ, Lin F, Bathgate RA, Tregear GW, Daly NL, Wade JD, et al. Solu-
tion structure and novel insights into the determinants of the receptor speci-
ficity of human relaxin-3. J Biol Chem (2006) 281:5845–51. doi:10.1074/jbc.
M511210200
14. Sudo S, Kumagai J, Nishi S, Layfield S, Ferraro T, Bathgate RA, et al. H3 relaxin
is a specific ligand for LGR7 and activates the receptor by interacting with
both the ectodomain and the exoloop 2. J Biol Chem (2003) 278:7855–62.
doi:10.1074/jbc.M212457200
15. Yan Y, Scott DJ, Wilkinson TN, Ji J, Tregear GW, Bathgate RA. Identifica-
tion of the N-linked glycosylation sites of the human relaxin receptor and
effect of glycosylation on receptor function. Biochemistry (2008) 47:6953–68.
doi:10.1021/bi800535b
16. Shabanpoor F, Hughes RA, Bathgate RAD, Zhang S, Scanlon DB, Lin F, et al.
Solid-phase synthesis of Europium-labeled human INSL3 as a novel probe for
the study of ligand-receptor interactions. Bioconjug Chem (2008) 19:1456–63.
doi:10.1021/bc800127p
17. Shabanpoor F, Bathgate RA, Belgi A, Chan LJ, Nair VB, Wade JD, et al. Site-
specific conjugation of a lanthanide chelator and its effects on the chemical
synthesis and receptor binding affinity of human relaxin-2 hormone. Biochem
Biophys Res Commun (2012) 420:253–6. doi:10.1016/j.bbrc.2012.02.141
18. Chen WB, Shields TS, Stork PJS, Cone RD. A colorimetric assay for measur-
ing activation of Gs- and Gq-coupled signaling pathways. Anal Biochem (1995)
226:349–54. doi:10.1006/abio.1995.1235
19. Blacklow SC. Versatility in ligand recognition by LDL receptor family proteins:
advances and frontiers. Curr Opin Struct Biol (2007) 17:419–26. doi:10.1016/j.
sbi.2007.08.017
20. Yasui N, Nogi T, Takagi J. Structural basis for specific recognition of Reelin by
its receptors. Structure (2010) 18:320–31. doi:10.1016/j.str.2010.01.010
21. Scott DJ, Rosengren KJ, Bathgate RA. The different ligand-binding modes of
relaxin family peptide receptors RXFP1 and RXFP2. Mol Endocrinol (2012)
26:1896–906. doi:10.1210/me.2012-1188
22. Hossain MA, Rosengren KJ, Haugaard-Jonsson LM, Zhang S, Layfield S, Ferraro
T, et al. The A-chain of human relaxin family peptides has distinct roles in the
binding and activation of the different relaxin family peptide receptors. J Biol
Chem (2008) 283:17287–97. doi:10.1074/jbc.M801911200
23. Wilkinson TN, Speed TP, Tregear GW, Bathgate RA. Coevolution of the relaxin-
like peptides and their receptors. Ann N Y Acad Sci (2005) 1041:534–9.
doi:10.1196/annals.1282.080
www.frontiersin.org November 2013 | Volume 4 | Article 171 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bruell et al. Chimeric RXFP1 and RXFP2 receptors
24. Wilkinson TN, Bathgate RA. The evolution of the relaxin peptide family and
their receptors. Adv Exp Med Biol (2007) 612:1–13. doi:10.1007/978-0-387-
74672-2_1
25. Nair VB, Samuel CS, Separovic F, Hossain MA, Wade JD. Human relaxin-2: his-
torical perspectives and role in cancer biology. Amino Acids (2012) 43:1131–40.
doi:10.1007/s00726-012-1375-y
26. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH,
et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart
failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet (2013)
381:29–39. doi:10.1016/S0140-6736(12)61855-8
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 26 September 2013; paper pending published: 20 October 2013; accepted: 25
October 2013; published online: 11 November 2013.
Citation: Bruell S, Kong RCK, Petrie EJ, Hoare B, Wade JD, Scott DJ, Gooley PR
and Bathgate RAD (2013) Chimeric RXFP1 and RXFP2 receptors highlight the simi-
lar mechanism of activation utilizing their N-terminal low-density lipoprotein class A
modules. Front. Endocrinol. 4:171. doi: 10.3389/fendo.2013.00171
This article was submitted to Molecular and Structural Endocrinology, a section of the
journal Frontiers in Endocrinology.
Copyright © 2013 Bruell, Kong , Petrie, Hoare, Wade, Scott , Gooley and Bathgate.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums is
permitted, provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice. No
use, distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Endocrinology | Molecular and Structural Endocrinology November 2013 | Volume 4 | Article 171 | 8
